secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001171843-25-003087
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeyondSpring Q1 net loss from continuing ops $2.6M; Plinabulin data show promise in PD-1 resistant cancers
--------------------------------------------------------------------------------

- Net loss from continuing ops $2.6M, up 24% YoY; R&D expense $0.9M, G&A $1.7M.
- Plinabulin combinations showed durable responses in metastatic NSCLC and Hodgkin lymphoma failing PD-1/L1 inhibitors.
- SEED's RBM39 degrader achieved complete tumor regression in Ewing sarcoma models; IND filing on track for mid-2025.
- SEED reported as discontinued ops after Jan 2025 sale of Series A-1 shares; BeyondSpring retains ~40% stake.
- Phase 1 trial of Plinabulin + PD-1 inhibitor + radiation at MD Anderson showed >19-month duration in heavily pretreated Hodgkin lymphoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325003087/0001171843-25-003087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325003087/f8k_051225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer